共 78 条
[1]
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin. 71 209-249
[2]
Ferlay J(2022)The New Era of Immunotherapy in Gastric Cancer Cancers (Basel). 14 1054-452
[3]
Siegel RL(2018)Regulation and Function of the PD-L1 Checkpoint Immunity. 48 434-192
[4]
Takei S(2022)Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation J Hematol Oncol. 15 24-40
[5]
Kawazoe A(2022)Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 20 167-1433
[6]
Shitara K(2021)First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet. 398 27-2107
[7]
Sun C(2021)Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors Front Oncol. 11 1425-641
[8]
Mezzadra R(2019)Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response Radiol Imaging Cancer. 1 2098-188
[9]
Schumacher TN(2021)Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients Radiol Med. 126 639-434
[10]
Wu M(2021)Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images Theranostics. 11 182-2471